Compare SEB & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEB | APGE |
|---|---|---|
| Founded | 1918 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | SEB | APGE |
|---|---|---|
| Price | $4,875.00 | $86.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $109.67 |
| AVG Volume (30 Days) | 9.2K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 467.71 | N/A |
| EPS | ★ 124.24 | N/A |
| Revenue | ★ $5,809,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.78 | ★ N/A |
| Revenue Growth | ★ 7.99 | N/A |
| 52 Week Low | $2,740.00 | $34.34 |
| 52 Week High | $5,989.37 | $95.32 |
| Indicator | SEB | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 54.52 |
| Support Level | $4,752.09 | $73.70 |
| Resistance Level | $5,183.91 | $93.61 |
| Average True Range (ATR) | 247.12 | 5.14 |
| MACD | -11.00 | 0.41 |
| Stochastic Oscillator | 7.25 | 68.32 |
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.